Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Richards

Showing results (31-40 of 736) with videos related to

Pageof 74
Sort By:
Journal of the American Heart Association|March 27, 2019
Do the Natriuretic Peptides Cause Atrial Fibrillation or is it Not So Black and White?Arthur Mark Richards
Canadian Journal of Physiology and Pharmacology|August 5, 2011
Tailored therapy for heart failure: neurohormonesA Mark Richards
Expert Opinion on Pharmacotherapy|November 16, 2011
Mineralocorticoid receptor antagonists for heart failureArthur Mark Richards
Evidence-Based Medicine|August 7, 2010
B-type natriuretic peptide-guided therapy for chronic heart failure reduces all-cause mortality compared with usual care but does not affect all-cause hospitalisation or survival free of hospitalisationA Mark Richards
Hypertension (Dallas, Tex. : 1979)|April 25, 2007
Natriuretic peptides: update on Peptide release, bioactivity, and clinical useA Mark Richards
Nature Reviews. Cardiology|October 17, 2018
Can heart failure cause cancer?A Mark Richards
Journal of the American College of Cardiology|September 13, 2008
Serial measurements of plasma B-type natriuretic peptides: what do they tell us?A Mark Richards
Heart Failure Clinics|October 14, 2015
Biomarkers for Heart Failure in AsiaArthur Mark Richards
Revista Espanola De Cardiologia (English Ed.)|November 9, 2015
Plasma Neprilysin Concentrations: A New Prognostic Marker in Heart Failure?A Mark Richards
Annals of the Academy of Medicine, Singapore|October 20, 2015
Angiotensin 2 Type 1 Receptor Blockade with Neprilysin Inhibition for Chronic Heart Failure: A New Paradigm?Arthur Mark Richards
Pageof 74

Showing results (31-40 of 736) with videos related to

Sort By:
Pageof 74
Journal of the American Heart Association|March 27, 2019
Do the Natriuretic Peptides Cause Atrial Fibrillation or is it Not So Black and White?Arthur Mark Richards
Canadian Journal of Physiology and Pharmacology|August 5, 2011
Tailored therapy for heart failure: neurohormonesA Mark Richards
Expert Opinion on Pharmacotherapy|November 16, 2011
Mineralocorticoid receptor antagonists for heart failureArthur Mark Richards
Evidence-Based Medicine|August 7, 2010
B-type natriuretic peptide-guided therapy for chronic heart failure reduces all-cause mortality compared with usual care but does not affect all-cause hospitalisation or survival free of hospitalisationA Mark Richards
Hypertension (Dallas, Tex. : 1979)|April 25, 2007
Natriuretic peptides: update on Peptide release, bioactivity, and clinical useA Mark Richards
Nature Reviews. Cardiology|October 17, 2018
Can heart failure cause cancer?A Mark Richards
Journal of the American College of Cardiology|September 13, 2008
Serial measurements of plasma B-type natriuretic peptides: what do they tell us?A Mark Richards
Heart Failure Clinics|October 14, 2015
Biomarkers for Heart Failure in AsiaArthur Mark Richards
Revista Espanola De Cardiologia (English Ed.)|November 9, 2015
Plasma Neprilysin Concentrations: A New Prognostic Marker in Heart Failure?A Mark Richards
Annals of the Academy of Medicine, Singapore|October 20, 2015
Angiotensin 2 Type 1 Receptor Blockade with Neprilysin Inhibition for Chronic Heart Failure: A New Paradigm?Arthur Mark Richards
Pageof 74